Download PDF
Z Gastroenterol 2021; 59(02): 117-124
DOI: 10.1055/a-1283-6966
Originalarbeit

Increased risk of ischemic heart disease and diabetes in inflammatory bowel disease

Erhöhtes Risiko für ischämische Herzerkrankungen und Diabetes bei entzündlichen Darmerkrankungen
Zhihui Li
  Department of Gastroenterology, The Second People’s Hospital of Liaocheng, the Second Hospital of Liaocheng affiliated to Shandong First Medical University, Liaocheng, Shandong Province, China
,
Lili Qiao
  Department of Gastroenterology, The Second People’s Hospital of Liaocheng, the Second Hospital of Liaocheng affiliated to Shandong First Medical University, Liaocheng, Shandong Province, China
,
Xiaojing Yun
  Department of Gastroenterology, The Second People’s Hospital of Liaocheng, the Second Hospital of Liaocheng affiliated to Shandong First Medical University, Liaocheng, Shandong Province, China
,
Fangjuan Du
  Department of Gastroenterology, The Second People’s Hospital of Liaocheng, the Second Hospital of Liaocheng affiliated to Shandong First Medical University, Liaocheng, Shandong Province, China
,
Shilei Xing
  Department of Gastroenterology, The Second People’s Hospital of Liaocheng, the Second Hospital of Liaocheng affiliated to Shandong First Medical University, Liaocheng, Shandong Province, China
,
Maowu Yang
  Department of Gastroenterology, The Second People’s Hospital of Liaocheng, the Second Hospital of Liaocheng affiliated to Shandong First Medical University, Liaocheng, Shandong Province, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Previous studies showed inconsistent results regarding associations between inflammatory bowel disease (IBD) and risk of ischemic heart disease (IHD) and diabetes. The present study aimed to make a meta-analysis to assess the risk of IHD and diabetes in IBD.

Methods We searched for articles published before February 2020 in the databases as follows: PubMed, Web of Science, Medline, EMBASE, and Google Scholar. We computed odds ratio (OR) or relative risk (RR) and 95 % confidence intervals (CI) regarding the association between IBD and risk of IHD or diabetes by using STATA 13.0 software.

Results The present meta-analysis showed that IBD was associated with higher risk of IHD (OR/RR = 1.26, 95 % CI 1.20 to 1.32, I2 = 88.3 %, p < 0.0001). Additionally, both ulcerative colitis (UC) and Crohn’s disease (CD) were associated with higher risk of IHD (UC: OR/RR = 1.19, 95 % CI 1.13 to 1.26, I2 = 65.6 %, p = 0.001; CD: OR/RR = 1.33, 95 % CI 1.17 to 1.51, I2 = 89.5 %, p < 0.0001). The study showed that IBD was associated with elevated risk of diabetes (OR/RR = 1.26, 95 % CI 1.03 to 1.53, I2 = 92.1 %, I2 = 92.1 %, p < 0.0001). Additionally, both UC and CD were associated with higher risk of diabetes (UC: OR/RR = 1.33, 95 % CI 1.03 to 1.71, I2 = 93.8 %, p < 0.0001; CD: OR/RR = 1.39, 95 % CI 1.10 to 1.76, I2 = 76.7 %, p = 0.002).

Conclusion In conclusion, patients with IBD are at increased risk of IHD and diabetes. Thus, regular monitoring of biomarkers of IHD and blood glucose levels should be considered for the early detection of IHD and diabetes in IBD patients.

Zusammenfassung

Hintergrund Frühere Studien zeigten inkonsistente Ergebnisse hinsichtlich der Zusammenhänge zwischen entzündlichen Darmerkrankungen (IBD) und dem Risiko einer ischämischen Herzerkrankung (IHD) und Diabetes. Die vorliegende Studie zielte darauf ab, eine Metaanalyse durchzuführen, um das Risiko von IHD und Diabetes bei IBD zu bewerten.

Methoden Wir haben nach Artikeln gesucht, die vor Februar 2020 in den Datenbanken wie folgt veröffentlicht wurden: PubMed, Web of Science, Medline, EMBASE und Google Scholar. Wir haben das Odds Ratio (OR) oder das relative Risiko (RR) und 95 %-Konfidenzintervalle (CI) in Bezug auf den Zusammenhang zwischen IBD und IHD- oder Diabetes-Risiken mithilfe der STATA 13.0-Software berechnet.

Ergebnisse Die vorliegende Metaanalyse zeigte, dass IBD mit einem höheren Risiko für IHD assoziiert war (OR/RR = 1,26, 95 % CI 1,20 bis 1,32, I2 = 88,3 %, p < 0,0001). Zusätzlich waren sowohl Colitis ulcerosa (UC) als auch Morbus Crohn (CD) mit einem höheren Risiko für IHD assoziiert (UC: OR/RR = 1,19, 95 % CI 1,13 bis 1,26, I2 = 65,6 %, p = 0,001; CD: OR/RR = 1,33, 95 % CI 1,17 bis 1,51, I2 = 89,5 %, p < 0,0001). Die Studie zeigte, dass IBD mit einem erhöhten Diabetes-Risiko assoziiert war (OR/RR = 1,26, 95 % CI 1,03 bis 1,53, I2 = 92,1 %, I2 = 92,1 %, p < 0,0001). Zusätzlich waren sowohl UC als auch CD mit einem höheren Diabetesrisiko assoziiert (UC: OR/RR = 1,33, 95 % CI 1,03 bis 1,71, I2 = 93,8 %, p < 0,0001; CD: OR/RR = 1,39, 95 % CI 1,10 bis 1,76, I2 = 76,7 %, p = 0,002).

Schlussfolgerung Zusammenfassend lässt sich sagen, dass Patienten mit IBD ein erhöhtes Risiko für IHD und Diabetes haben. Daher sollte eine regelmäßige Überwachung der Biomarker für IHD und Blutzuckerspiegel in Betracht gezogen werden, um IHD und Diabetes bei IBD-Patienten frühzeitig zu erkennen.

Key words

inflammatory bowel disease - ischemic heart disease - diabetes - meta-analysis

Schlüsselwörter

entzündliche Darmerkrankungen - ischämische Herzerkrankungen - Diabetes - Metaanalyse

Supplement



Publication History

Received: 25 June 2020

Accepted: 11 September 2020

Article published online:
24 November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it?. World J Gastroenterol 2009; 15: 4234-4239
    CrossrefPubMedGoogle Scholar
  • 2 Singh S, Singh H, Loftus Jr EV. et al. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 382-393.e381: quiz e322
    CrossrefPubMedGoogle Scholar
  • 3 Fumery M, Xiaocang C, Dauchet L. et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 2014; 8: 469-479
    CrossrefPubMedGoogle Scholar
  • 4 Dregan A, Charlton J, Chowienczyk P. et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 2014; 130: 837-844
    CrossrefPubMedGoogle Scholar
  • 5 Jess T, Jensen BW, Andersson M. et al. Inflammatory bowel disease increases risk of type 2 diabetes in a nationwide cohort study. Clin Gastroenterol Hepatol 2019; 18: 881-888
    CrossrefPubMedGoogle Scholar
  • 6 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed.) 2009; 339: b2535
    CrossrefPubMedGoogle Scholar
  • 7 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2000-2012
    CrossrefPubMedGoogle Scholar
  • 8 Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol 2008; 6: 41-45
    CrossrefPubMedGoogle Scholar
  • 9 Osterman MT, Yang YX, Brensinger C. et al. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn’s disease. Clin Gastroenterol Hepatol 2011; 9: 875-880
    CrossrefPubMedGoogle Scholar
  • 10 Yarur AJ, Deshpande AR, Pechman DM. et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol 2011; 106: 741-747
    CrossrefPubMedGoogle Scholar
  • 11 Rungoe C, Basit S, Ranthe MF. et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2013; 62: 689-694
    CrossrefPubMedGoogle Scholar
  • 12 Zöller B, Li X, Sundquist J. et al. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PloS one 2012; 7: e33442
    CrossrefPubMedGoogle Scholar
  • 13 Kristensen SL, Ahlehoff O, Lindhardsen J. et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study. PloS one 2013; 8: e56944
    CrossrefPubMedGoogle Scholar
  • 14 Tsai MS, Lin CL, Chen HP. et al. Long-term risk of acute coronary syndrome in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population. Inflamm Bowel Dis 2014; 20: 502-507
    CrossrefPubMedGoogle Scholar
  • 15 Close H, Mason JM, Wilson DW. et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: cohort study using the general practice research database. PloS one 2015; 10: e0139745
    CrossrefPubMedGoogle Scholar
  • 16 McAuliffe ME, Lanes S, Leach T. et al. Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database. Cur Med Res Opin 2015; 31: 1655-1664
    CrossrefPubMedGoogle Scholar
  • 17 Feng W, Chen G, Cai D. et al. Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies. J Am Heart Assoc 2017; 6: e005892
    CrossrefPubMedGoogle Scholar
  • 18 Choi HW, Kim HR, Baek HJ. et al. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia. Ann Lab Med 2015; 35: 118-122
    CrossrefPubMedGoogle Scholar
  • 19 Kappelman MD, Galanko JA, Porter CQ. et al. Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child 2011; 96: 1042-1046
    CrossrefPubMedGoogle Scholar
  • 20 Virta LJ, Kolho KL. The risk of contracting pediatric inflammatory bowel disease in children with celiac disease, epilepsy, juvenile arthritis and type 1 diabetes – a nationwide study. J Crohns Colitis 2013; 7: 53-57
    CrossrefPubMedGoogle Scholar
  • 21 Kang EA, Han K, Chun J. et al. Increased risk of diabetes in inflammatory bowel disease patients: a nationwide population-based study in Korea. J Clin Med 2019; 8: 343
    PubMedGoogle Scholar
  • 22 Matsuura E, Atzeni F, Sarzi-Puttini P. et al. Is atherosclerosis an autoimmune disease?. BMC Med 2014; 12: 47
    CrossrefPubMedGoogle Scholar
  • 23 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med 2005; 352: 1685-1695
    CrossrefPubMedGoogle Scholar
  • 24 Roberts-Thomson IC, Fon J, Uylaki W. et al. Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol 2011; 5: 703-716
    CrossrefPubMedGoogle Scholar
  • 25 Wu GC, Leng RX, Lu Q. et al. Subclinical atherosclerosis in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Angiology 2017; 68: 447-461
    CrossrefPubMedGoogle Scholar
  • 26 Zanoli L, Cannavò M, Rastelli S. et al. Arterial stiffness is increased in patients with inflammatory bowel disease. J Hypertens 2012; 30: 1775-1781
    CrossrefPubMedGoogle Scholar
  • 27 Roifman I, Sun YC, Fedwick JP. et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7: 175-182
    CrossrefPubMedGoogle Scholar
  • 28 Souverein PC, Berard A, Van Staa TP. et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 859-865
    CrossrefPubMedGoogle Scholar
  • 29 Davis 3rd JM, Maradit KremersH, Crowson CS. et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 56: 820-830
    CrossrefPubMedGoogle Scholar
  • 30 Abrahami D, Douros A, Yin H. et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ (Clinical research ed.) 2018; 360: k872
    Google Scholar
  • 31 Galluzzo S, Patti G, Dicuonzo G. et al. Association between NOD2 / CARD15 polymorphisms and coronary artery disease: a case-control study. Hum Immunol 2011; 72: 636-640
    CrossrefPubMedGoogle Scholar
  • 32 Parkes M, Barrett JC, Prescott NJ. et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat Genet 2007; 39: 830-832
    CrossrefPubMedGoogle Scholar
  • 33 Anderson CA, Boucher G, Lees CW. et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-252
    CrossrefPubMedGoogle Scholar
  • 34 Festen EA, Goyette P, Scott R. et al. Genetic variants in the region harbouring IL2 / IL21 associated with ulcerative colitis. Gut 2009; 58: 799-804
    CrossrefPubMedGoogle Scholar
  • 35 Franke A, Balschun T, Sina C. et al. Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat Genet 2010; 42: 292-294
    CrossrefPubMedGoogle Scholar
  • 36 Franke A, Balschun T, Karlsen TH. et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008; 40: 1319-1323
    CrossrefPubMedGoogle Scholar
  • 37 Barrett JC, Hansoul S, Nicolae DL. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 2008; 40: 955-962
    CrossrefPubMedGoogle Scholar
  • 38 Imielinski M, Baldassano RN, Griffiths A. et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009; 41: 1335-1340
    CrossrefPubMedGoogle Scholar
  • 39 Horikawa Y, Oda N, Cox NJ. et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26: 163-175
    CrossrefPubMedGoogle Scholar
  • 40 Allin KH, Tremaroli V, Caesar R. et al. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia 2018; 61: 810-820
    CrossrefPubMedGoogle Scholar
  • 41 Arif S, Moore F, Marks K. et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. Diabetes 2011; 60: 2112-2119
    CrossrefPubMedGoogle Scholar